The  Impact  of  Beta-blockade  on  Right  Ventricular  Function  in  Mitral  Regurgitation by Hongning, Yin et al.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/authorsrights
Author's personal copy
The Impact of Beta-blockade on Right
Ventricular Function in Mitral
Regurgitation
Yin Hongning a, Ralph A. Stewart b, Gillian A. Whalley c*
aThe 2nd Hospital of Hebei Medical University, Shijiazhuang, China
bAuckland City Hospital, Auckland, New Zealand
cUnitec, Auckland, New Zealand
Received 8 April 2013; received in revised form 11 October 2013; accepted 22 October 2013; online published-ahead-of-print 1 November 2013
Introduction
Degenerative mitral regurgitation (MR) results in left ven-
tricular (LV) volume overload and LV dysfunction that con-
tributes to prognosis [1]. RV function is also prognostically
important [2]: tricuspid annular plane systolic excursion
(TAPSE), a measure of systolic annular descent, is correlated
with RV ejection fraction (RVEF) [3] and predicts survival
after mitral valve repair [4].
In patients with LV systolic dysfunction, beta-blockade
improves prognosis [5] and reverses adverse LV remodelling
[6], potentially mediated through a long-term reduction
in myocyte strain, also seen with MR-related chronic LV
volume overload [7]. Recently, we reported that short-term
beta-blocker treatment did not change MR volume but
decreased LV work in patients with moderate-severe MR
[8]. The aim of this study was to investigate the influence
of short-term beta-blocker on RV.
Patients and Methods
The methods have been reported elsewhere [8]. Briefly,
patients with moderate-severe MR, normal LV systolic func-
tion (echo LV ejection fraction >55%) and sinus rhythm were
recruited into this double-blind, randomised, crossover
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Background Although mitral regurgitation (MR) results in left ventricular (LV) volume overload, right ventricular (RV)
function may also be impaired. We investigated the influence of short-term beta-blockade on RV function in
patients with moderate-severe MR.
Methods Twenty-six patients were randomised in a cross-over design to receive two weeks of beta-blockade or
placebo. Echocardiography was performed at baseline and at the end of the treatment periods. Measure-
ments included: RV ejection fraction (RVEF) tricuspid annular motion and Tei index.
Results No differences in mean RVEF (64.0  6.0 v 67.0  8.0%, p = 0.3), tricuspid annular motion (13.5  3.0 v 14.7
 2.9 cm/s, p = 0.5), or median Tei index (0.61 (0.54, 0.88) v 0.59 (0.54, 0.74), p = 0.8) were observed between
placebo and metoprolol, despite significantly longer cardiac time intervals. Tei index under both conditions
was significantly reduced.
Conclusions Short-term treatment with a beta-blocker did not influence RV function in these patients. Interestingly, the
RV Tei index was high suggesting significant RV dysfunction despite normal RVEF.
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design trial which had two treatment periods (14  3 days)
with a two to four days washout between treatments. Sub-
jects were randomised to extended-release metoprolol or
placebo or vice versa. The initial dose was one continuous-
release metoprolol tablet (47.5 mg) or placebo per day. The
dose was increased every three to four days if the patient had
no side effects, resting heart rate was 360 bpm, and systolic
blood pressure was 3110 mm Hg, with a maximum dose of
190 mg/d. The dose was reduced if clinically indicated. All
other medication was unchanged throughout. At baseline,
and the end of each study period, clinical examination, ECG,
and echocardiography were completed. Echocardiographic
measurements were performed blind: RVEF (area-length
method, apical four-chamber view); 2D TAPSE; pulsed-wave
tissue Doppler imaging (TDI) of longitudinal RV free wall
annular motion (systolic (Sm), early diastolic (Em), late dia-
stolic (Am) velocities); Tei index (Tei index = (isovolumetric
contraction time + isovolumic relaxation time)/ejection
time). Similar measurements were obtained from the LV
by both conventional and tissue Doppler (septal and lateral
walls) methods. From the TDI recordings, the time interval
from the end of one to the onset of the next tricuspid annular
velocity pattern during diastole (a) was measured. The dura-
tion of the Sm (b) was measured from the onset to the end of
the Sm. The Tei index was calculated as (a  b)/b. Very few
patients had sufficient tricuspid regurgitation to allow mea-
surement of RV systolic pressure.
Statistical Analysis
Continuous variables were compared by treatment arm
using paired Student t-tests (Wilcoxon for non-parametric
data). Pearson correlation coefficients are reported, with a
value of p < 0.05 was considered statistically significant.
Results
Twenty-six patients were enrolled: mean age 61  10 years;
seven patients had mild dyspnoea on exertion (NYHA class
IIa); 12 reported a history of treated hypertension. Most
patients had posterior mitral leaflet prolapse (Table 1). Heart
rate was significantly lower on metoprolol (65  10 bpm)
compared to placebo (55  7 bpm), but no significant
changes in RV volumes or function were observed (Table
2). Tei index was similar on metroprolol and placebo, despite
there being a significantly longer a time (519 v 476, p = 0.005)
and a trend towards longer b time (309 v 299, p = 0.07).
Similar results were observed for LV Tei index (Table 2).
Tei index under both conditions was significantly different to
the published normal values for RV Tei index (0.28  0.04 by
conventional Doppler [9] and 0.43  0.07 [10]. We have pre-
viously reported no impact on LV volumes and EF [8] but this
study confirmed similar stable results for LV parameters and
also elevated LV Tei index (Table 2). The LV Tei index values
are significantly different to the published normal values
(0.33  0.09 by conventional Doppler and 0.42  0.09 by
TDI [11]).
Discussion
We have demonstrated that RV function in patients with MR
is not influenced by short-term beta-blocker treatment. How-
ever, the RV Tei indices were substantially higher than
reported normal values [9], suggesting significant RV dys-
function despite normal RVEF. Thus, the Tei index, a mea-
sure of global cardiac function [9], might be a more sensitive
parameter to estimate the RV dysfunction. Similar results
were observed for the LV Tei index.
This was a small study, possibly underpowered that is
mostly hypothesis generating. We have used some published
normal values for RV Tei and it is acknowledged that includ-
ing our own control group would have been optimal. Future
work should validate the Tei index measured from Tissue
Doppler in this setting against a control series, should
include more complex assessment of systolic time intervals,
and ideally should include 3D echo and global longitudinal
strain.
Early detection of ventricular dysfunction is crucial in the
setting of severe MR: by the time LV dysfunction is apparent
using conventional echocardiography it is often irreversible.
Table 1 Demographic and Clinical Characteristics of
the Study Population.
Characteristic Whole group
(N = 26)
Age, years 61  10
Male, n (%) 21 (84)
Ethnic group, n (%)
White 20 (80)
Maori/Pacific Islander 3 (12)
Other 2 (8)
Body mass index, kg/m2 25.8  3.8
History of hypertension, n (%) 12 (48)
Medical treatment during study
ACE inhibitor, n (%) 11 (44)
Loop diuretic, n (%) 1 (4)
Symptoms
Asymptomatic, n (%) 19 (73)
NYHA class a symptoms, n (%) 7 (28)
Leaflet prolapse
Anterior leaflet, n (%) 2 (8)
Posterior leaflet, n (%) 14 (56)
Bileaflet, n (%) 9 (36)
Flail or partial flail mitral leaflet, n (%) 11 (44)
Echocardiography
LV end-systolic volume, mL 81  21
LV end-diastolic volume, mL 229  50
LV ejection fraction, % 65  5
Mitral regurgitant volume, mL 59  36
Data are mean  SD or number (percentage).
Abbreviations: ACE, angiotensin-converting enzyme; NYHA, New York
Heart Association.
The Impact of Beta-blockade on Right Ventricular Function in Mitral Regurgitation 379
Author's personal copy
However, if more objective measures of both RV and LV
systolic dysfunction were available, perhaps a more precise
management might be obtainable.
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Table 2 Effects of Metoprolol on Heart Rate and Ventricular Function.
Placebo (N = 26) Metoprolol (N = 26) p value
Heart rate, bpm 65  10 55  7 <0.0001
RV end-systolic volume, mL 19.1  7.5 18.3  8.3 0.7
RV end-diastolic volume, mL 52.9  18.9 55.8  18.1 0.5
RV ejection fraction, % 64.0  6.0 67.0  8.0 0.3
RV TAPSE, cm 2.57  0.34 2.63  0.40 0.9
Tricuspid systolic annular velocity, cm/s 13.5  3.0 14.7  2.9 0.5
TDI RV Em/Am 0.87 (0.75–1.43) 0.81 (0.65–1.13) 0.97
TDI RV time a, ms 476 (443–493) 519 (492–535) 0.005
TDI RV time b, ms 299 (262–312) 309 (293–339) 0.07
TDI RV Tei index 0.61 (0.54–0.88) 0.59 (0.54–0.74) 0.8
Left ventricular Tei measurements
Mitral LV time a, ms 432.7  48.0 455.8  53.5 0.003
Mitral LV time b, ms 261.6  32.5 271.6  36.2 0.009
Mitral LV Tei index 0.68 (0.58–0.81) 0.61 (0.52–0.80) 0.59
TDI (lateral) LV time a, ms 446.3  60.7 506.4  50.6 0.005
TDI (lateral) LV time b, ms 275.5  46.8 299.3  39.9 0.003
TDI (lateral) LV Tei index 0.64 (0.57–0.84) 0.67 (0.57–0.78) 0.97
TDI (septal) LV time a, ms 477.8  54.3 494.8  52.5 0.115
TDI (septal) LV time b, ms 295.9  34.6 314.5  34.7 0.007
TDI (septal) LV Tei index 0.62 (0.57–0.69) 0.56 (0.50–0.67) 0.19
Abbreviations: a, the time interval from the end of one to the onset of the next tricuspid annular velocity pattern during diastole; b, duration of systole using systolic
annular velocity; Am, late mitral annular velocity; Em, early mitral annular velocity; LV, left ventricle; RV, right ventricle; TAPSE, tricuspid annular plane systolic
excursion; Data are mean  standard deviation or median (95% confidence interval).
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